MicroRNA in prostate cancer: from biogenesis to applicative potential
- PMID: 39506720
- PMCID: PMC11539483
- DOI: 10.1186/s12894-024-01634-1
MicroRNA in prostate cancer: from biogenesis to applicative potential
Abstract
Prostate cancer is the most common solid malignant tumor in men, characterized by high morbidity and mortality. While current screening tools, such as prostate-specific antigen (PSA) testing and digital rectal examination, are available for early detection of prostate cancer, their sensitivity and specificity are limited. Tissue puncture biopsy, although capable of offering a definitive diagnosis, has poor positive predictive rates and burdens the patient more. Therefore, more reliable molecular diagnostic tools for prostate cancer urgently need to be developed. In recent years, microRNAs (miRNAs) have attracted much attention in prostate cancer research. miRNAs are extensively engaged in biological processes such as cell proliferation, differentiation, apoptosis, migration, and invasion by modulating gene expression post-transcriptionally. Dysregulation of miRNA expression in cancer is considered a critical factor in tumorigenesis and progression. This review first briefly introduces the biogenesis of miRNAs and their functions in cancer, then focuses on tumor-promoting miRNAs and tumor-suppressor miRNAs in prostate cancer. Finally, the potential application of miRNAs as multifunctional tools for cancer diagnosis, prognostic assessment, and therapy is discussed in detail. The concluding section summarizes the major points of the review and the challenges ahead.
Keywords: Biomarkers; Diagnosis; MicroRNAs; Prognosis; Prostate cancer; Therapy.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures
Similar articles
-
Role of miRNA-145, 148, and 185 and Stem Cells in Prostate Cancer.Int J Mol Sci. 2022 Jan 30;23(3):1626. doi: 10.3390/ijms23031626. Int J Mol Sci. 2022. PMID: 35163550 Free PMC article. Review.
-
MicroRNAs in prostate cancer: From function to biomarker discovery.Exp Biol Med (Maywood). 2018 Jun;243(10):817-825. doi: 10.1177/1535370218775657. Exp Biol Med (Maywood). 2018. PMID: 29932371 Free PMC article. Review.
-
The role of miRNA in prostate cancer diagnosis, prognosis and treatment response: a narrative review.Future Oncol. 2023 Jan;19(1):77-93. doi: 10.2217/fon-2022-0891. Epub 2023 Jan 27. Future Oncol. 2023. PMID: 36705257 Review.
-
Circulating miRNAs 21 and 221 as biomarkers for early diagnosis of prostate cancer.Tumour Biol. 2014 Dec;35(12):12613-7. doi: 10.1007/s13277-014-2584-7. Epub 2014 Sep 5. Tumour Biol. 2014. PMID: 25190021
-
MicroRNAs as biomarkers for early diagnosis, targeting and prognosis of prostate cancer.Pathol Res Pract. 2023 Aug;248:154618. doi: 10.1016/j.prp.2023.154618. Epub 2023 Jun 13. Pathol Res Pract. 2023. PMID: 37331185 Review.
Cited by
-
Overdiagnosis and Overtreatment in Prostate Cancer.Diseases. 2025 May 24;13(6):167. doi: 10.3390/diseases13060167. Diseases. 2025. PMID: 40558578 Free PMC article. Review.
-
MiR-135a-3p inhibits the progression of prostate cancer by targeting TLR4.Cancer Biol Ther. 2025 Dec;26(1):2545653. doi: 10.1080/15384047.2025.2545653. Epub 2025 Aug 22. Cancer Biol Ther. 2025. PMID: 40843910 Free PMC article.
References
-
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. 10.3322/caac.21708. - PubMed
-
- Van Poppel H, Albreht T, Basu P, Hogenhout R, Collen S, Roobol M. Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future. Nat Rev Urol. 2022;19(9):562–72. 10.1038/s41585-022-00638-6. - PubMed
-
- Crawford ED. Epidemiology of prostate cancer. Urology. 2003;62(6 Suppl 1):3–12. 10.1016/j.urology.2003.10.013. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous